(Health-NewsWire.Net, August 24, 2017 ) The Middle-East & Africa Therapeutic Vaccines Market is estimated at $96.60 Million in 2016, and is poised to reach $450.89 Million by 2021 with a CAGR of 36.09%. Currently, in pipeline several approaches are being developed in order to boost the immune response to various infectious and cancerous cells. There are presently close to 120 new vaccines in the pipeline of various multinational companies across the globe set to hit the market in the next few years.
View Full Report @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-therapeutic-vaccines-market-80/
HIV/AIDS is a major public health concern and COD in many parts of Africa. Although the continent is home to about 15.2 percent of the world's population, Sub-Saharan Africa alone accounted for an estimated 69 percent of all people living with HIV and 70 percent of all AIDS deaths in 2011. Recently, Aids treatment has shown promising results in a clinical trial in South Africa. The therapeutic vaccine makes antiviral drugs more effective by boosting the immune system of people living with the Aids virus, HIV. This probably marks the significant growth of therapeutic vaccines in the African sub -continent given the serious levels AIDS infected population. Combining this with the spending ability of Middle East economies coupled with their recently booming markets makes this region a lucrative one for the market players.
Increase in funding’s from government for vaccine development, rise in investments by the major market players, rising prevalence of disease, technological advancements, initiatives by NGO’s are some of the factors that are propelling the market growth. However, massive capital expenditures and stringent regulatory policies, high cost associated with treatment are few factors inhibiting the growth of the market.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-therapeutic-vaccines-market-80/request-sample
In Middle-East & Africa, the Therapeutic Vaccines Market is segmented by the type of disease into Autoimmune Disease Vaccines (Type I Diabetes), Cancer Vaccines (Multikine, PR1 Peptide Vaccine, TroVax, CYT004-MelQbG10 etc.), Neurological Disease Vaccines (ACC-001, CAD106, Parkinson’s Disease Vaccine, Alzheimer's Disease and Other Disease Vaccines), and Infectious Disease Vaccines (Hepatitis C, HIV/AIDS and Other Infectious Disease Vaccines). On the basis of geography, the Middle-East & Africa Market is analysed under major regions of Middle-East and Africa.
Some of the key players influencing the Middle-East & Africa preventive vaccine market are GlaxoSmithKline, plc., Merck and Company, Bavarian Nordic, CSL Limited, Emergent BioSolutions Inc., Novartis AG, Johnson and Johnson, MedImmune, LLC, Pfizer, Inc., and Sanofi Pasteur.
Inquire before Buying @ http://www.marketdataforecast.com/market-reports/middle-east-and-africa-therapeutic-vaccines-market-80/inquire
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com
|